CompareInsitrovsRecursion

Insitro is a machine-learning drug discovery company for pharmaceutical partners, combining proprietary biological data generation with predictive modeling to support selected target discovery and R&D programs.

1. Operating model: Engagement is partnership-led rather than self-serve, making it most relevant to organizations prepared for complex collaborative, long-term discovery work.
2. Scientific approach: Its platform combines integrated computational biology, proprietary human-cell data, machine learning, and wet-lab integration across drug-target workflows.
3. Evaluation priorities: Buyers should assess data-access requirements, expected timelines to validated leads, and program-specific cost structures across proposed collaborations.
4. Commercial considerations: Pricing is sales-led and scoped per buyer; confirm program fit, workflow requirements, implementation support, and collaboration scope before committing.

For data-rich discovery programs, the key question is whether Insitro's partnership model and technical depth match the buyer's overall scientific and operational needs.

Recursion is an AI drug discovery company for pharma collaborators and internal programs, combining cellular imaging, automation, and machine learning to identify potential drug candidates.

1. Scientific approach: The platform centers on phenomics and multimodal data, supporting computational biology and R&D acceleration rather than guaranteeing clinical outcomes.
2. Engagement model: Access typically occurs through pharma partnerships instead of self-serve subscriptions, making it relevant to organizations prepared for collaborative discovery.
3. Evaluation priorities: Buyers should examine data-access requirements, timelines to validated leads, validation depth, support coverage, and program-specific costs before committing.
4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, while direct buyer access remains limited to partnerships.

Its fit depends on whether Recursion’s data-rich discovery model, partnership structure, and development timelines align with the buyer’s overall program goals.